

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
 (Use several sheets if necessary)

 Docket Number (Optional)
 APV-340.04

 Application Number
 09/676,834

 Applicant
 Michael Z. Gilman

APR 09 2002

 Filing Date
 September 29, 2000

 Group Art Unit
 1636

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
On	AA	5,464,758	11/7/95	Gossen et al.	435	69.1
On	AB	5,654,168	8/5/97	Bujard et al.	435	69.1
On	AC	5,741,899	4/21/98	Capon et al.	536	23.4
On	AD	5,830,462	11/3/98	Crabtree et al.	424	93.21
On	AE	5,851,999	12/22/98	Ulrich et al.	514	44
On	AF	5,945,403	8/31/99	Folkman et al.	514	21

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
On	AG	96/06111	2/29/96	WO			
On	AH	96/41865	12/27/96	WO			
On	AI	98/13071	4/2/98	WO			
On	AJ	96/25953	8/29/96	WO			
On	AK	94/18317	8/18/94	WO			
On	AL	96/04389	2/15/96	WO			
On	AM	95/02684	1/26/95	WO			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

On	AN	Young, K.H. et al. (1995), <i>Investigation of Ligand Binding to Members of the Cytokine Receptor Family Within a Microbial System</i> , ANN. NY ACAD. SCI. 766:279-81.					
On	AO	Ozenberger, B.A. et al. (1995), <i>Functional Interaction of Ligands and Receptors of the Hematopoietic Superfamily in Yeast</i> , MOL. ENDOCRINOL. 9:1321-29.					
On	AP	Burcin, M.M. et al. (1999), <i>Adenovirus-mediated Regulable Target Gene Expression in vivo</i> , PROC. NATL. ACAD. SCI. USA 96:355-60.					
On	AQ	Rivera, V.M. et al. (1996), <i>A Humanized System for Pharmacologic Control of Gene Expression</i> , NATURE MED. 2(9):1028-32.					
On	AR	Rivera, V.M. et al. (1999), <i>Long-term Regulated Expression of Growth Hormone in Mice After Intramuscular Gene Transfer</i> , PROC. NATL. ACAD. SCI. USA 96:8657-62.					
On	AS	Rendahl, K.G. et al. (1998), <i>Regulation of Gene Expression in vivo Following Transduction by Two Separate rAAV Vectors</i> , NATURE BIOTECH. 16:757.					
On	AT	Ye, X. et al. (1999), <i>Regulated Delivery of Therapeutic Proteins After in vivo Somatic Cell Gene Transfer</i> , SCIENCE 283:88.					

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

APV-340.04

Application Number

09/676,834

Applicant

Michael Z. Gilman

Filing Date

September 29, 2000

Group Art Unit

1636

Maisonpierre, P. et al. (1997), *Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis*, SCIENCE 275:86.

AU

Millauer, B. et al. (1994), *Glioblastoma Growth Inhibited in vivo by a Dominant-Negative Flk-1 Mutant*, NATURE 367:576.

AV

Lin, P. et al. (1998), *Inhibition of Tumor Growth By Targeting Tumor Endothelium Using a Soluble Vascular Endothelial Growth Factor Receptor*, CELL GROWTH & DIFFERENTIATION 9:49-58.

AW

Kendall, R.L. et al. (1993), *Inhibition of Vascular Endothelial Cell Growth Factor Activity by an Endogenously Encoded Soluble Receptor*, PROC. NATL. ACAD. SCI. USA 90:10705-09.

AX

Waltenberger, J. (1997), *Modulation of Growth Factor Action*, CIRCULATION 96(11):4083-94.

AY

Clapp, C. et al. (1993), *The 16-Kilodalton N-Terminal Fragment of Human Prolactin is a Potent Inhibitor of Angiogenesis*, ENDOCRINOLOGY 133(3):1292.

AZ

Cao, Y. et al. (1998), *Expression of Angiostatin cDNA in a Murine Fibrosarcoma Suppresses Primary Tumor Growth and Produces Long-Term Dormancy of Metastases*, J. CLIN. INVEST. 101(5):1055-63.

BA

O'Reilly, M.S. et al. (1997), *Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth*, CELL 88:277-85.

BB

O'Reilly, M.S. et al. (1994), *Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma*, CELL 79:315-28.

BC

Kim, K.J. et al. (1993), *Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor Growth in vivo*, NATURE 362:841.

BD

Qi, J. et al. (1995), *The Ligand-Binding Domains of the Thyroid Hormone/Retinoid Receptor Gene Subfamily Function in vivo to Mediate Heterodimerization, Gene Silencing, and Transactivation*, MOLECULAR & CELLULAR BIO. 15(3):1817-25.

BE

Bergmann, K.E. et al. (1994), *Bivalent Ligands as Probes of Estrogen Receptor Action*, J. STEROID BIOCHEM. MOLEC. BIO. 49:139-52.

BF

Liu, J. (1993), *FK506 and Cyclosporin, Molecular Probes for Studying Intracellular Signal Transduction*, IMMUNOLOGY TODAY 14(6):290-95.

BG

Orloff, D.G. et al. (1990), *Family of Disulphide-Linked Dimers Containing the ζ and η Chains of the T-Cell Receptor and the γ Chain of Fc Receptors*, NATURE 347:189.

BH

Orkin, S.H. et al. (1995), *Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy*, NATL. INST. OF HEALTH.

BI

Weintraub, H. et al. (1991), *The myoD Gene Family: Nodal Point During Specification of the Muscle Cell Lineage*, SCIENCE 251:761-66.

BJ

Rutledge, T. et al. (1992), *Transmembrane Helical Interactions: Zeta Chain Dimerization and Functional Association with the T Cell Antigen Receptor*, EMBO J. 11:3245-54.

BK

Form PTO-1449

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)
APV-340.04Application Number
09/676,834Applicant
Michael Z. GilmanFiling Date
September 29, 2000Group Art Unit
1631Sadowski, H.B. et al. (1998), *Calcitonin Receptor-Like Receptor Free Activation of a DNA-Binding Protein by Epidermal Growth Factor*, NATURE 362:79.

BL

EXAMINER

DATE CONSIDERED

RECEIVED

EXAMINER: Initial if citation considered prior or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

TECH CENTER 1600/2900

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE